Case report of the dupilumab applying in atopic dermatitis child

Cover Page

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In recent years, there has been a clear trend towards an increase in the number of patients with severe atopic dermatitis. In most cases, patients are dissatisfied with the previous therapy, which requires hospital treatment to relieve acute manifestations of atopic dermatitis and the selection of pharmacological agents aimed at achieving long-term control under the of the disease symptoms

The article presents the features of the atopic dermatitis therapy of at the present stage, the experience of using the new biological drug dupilumab in a 7-year-old child.

Full Text

Restricted Access

About the authors

Vera A. Revyakina

The Federal Research Center for Nutrition, Вiotechnology and Food Safety

Author for correspondence.
Email: 5356797@mail.ru
ORCID iD: 0000-0002-1149-7927
SPIN-code: 4607-0540

MD, Dr. Sci. (Med.), Professor, Head of Allergy Department

Russian Federation, Moscow, 115445

Inna A. Larkova

The Federal Research Center for Nutrition, Вiotechnology and Food Safety

Email: inna_larkova@mail.ru
ORCID iD: 0000-0001-7640-0754
SPIN-code: 2991-3774

MD, Cand. Sci. (Med.), Senior researcher of Allergy Department

Russian Federation, Moscow, 115445

Elena D. Kuvshinova

The Federal Research Center for Nutrition, Вiotechnology and Food Safety

Email: len.kuwshinowa@yandex.ru
ORCID iD: 0000-0003-3650-6305
SPIN-code: 8403-2424

MD, Cand. Sci. (Med.), Senior Research Associate

Russian Federation, Moscow, 115445

Valery A. Mukhortykh

The Federal Research Center for Nutrition, Вiotechnology and Food Safety

Email: valera-89@yandex.ru
ORCID iD: 0000-0001-8549-9493
SPIN-code: 3437-4081

Junior Research Associate

Russian Federation, Moscow, 115445

Kseniya S. Melnikova

The Federal Research Center for Nutrition, Вiotechnology and Food Safety

Email: melnikova_ksenya85@bk.ru
ORCID iD: 0000-0002-6583-0545
Russian Federation, Moscow, 115445

References

  1. Allergology and Immunology: a national guide. Ed. by R.M. Khaitov, N.I. Ilyina. Moscow : GEOTAR-Media; 2009. 659 p. (In Russ).
  2. RAAKI. Russian Society of Dermatovenerologists and Cosmetologists (project). Atopic dermatitis. Clinical recommendations. Union of Pediatricians of Russia. 2020. (In Russ). Available from:https://raaci.ru/education/clinic_recomendations/100.html
  3. Kubanov AA, Bogdanova EV. Organization and results of medical care in the field of dermatovenerology in the Russian Federation. Results of 2018. Bulletin of Dermatology and Venereology. 2019;95(4):8–23. (In Russ). doi: 10.25208/0042-4609-2019-95-4-8-23
  4. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019;129(4):1493–1503. doi: 10.1172/JCI124611
  5. Revyakina VA, Ivanova EV, Kuvshinova ED, Larkova IA. Influence of family psychological factors on the course of atopic dermatitis in children. Pediatrics. The journal named after G.N. Speransky. 2018;97(2):38–43. (In Russ). doi: 10.24110/0031-403X-2018-97-2-38-43
  6. Tamrazova OB. Pathogenetic therapy of children suffering from severe forms of atopic dermatitis. Russian Medical Journal. Pediatrics. 2013;21(2):108–114. (In Russ).
  7. Larkova IA. Effective therapy of atopic dermatitis in children complicated by secondary infection. Medical advice. 2016;1:162–167. (In Russ). doi: 10.21518/2079-701X-2016-1-162-167
  8. Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7(1):1–23. doi: 10.1007/s13555-016-0170-1
  9. Ilina NI, Gudima GO. Targeted therapy – the future of allergology and clinical immunology. Russian Allergological Journal. 2014;4:69–75. (In Russ).
  10. Simon D, Hösli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008;121(1):122–128. doi: 10.1016/j.jaci.2007.11.016
  11. Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60(5):693–696. doi: 10.1111/j.1398-9995.2005.00791.x
  12. Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55(1):168–170. doi: 10.1016/j.jaad.2005.12.045
  13. Ruzicka T, Hanifin JM, Furue M, et al; XCIMA Study Group. Anti-Interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826–835. doi: 10.1056/NEJMoa1606490
  14. Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol. 2007;120(5):1223–1225. doi: 10.1016/j.jaci.2007.08.060
  15. Ilina NI, Kurbacheva OM. Monoclonal antibodies in the system of anti-asthmatic treatment. Russian Allergological Journal. 2018;15(3):5–15. (In Russ).
  16. Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75(2):311–325. doi: 10.1111/all.13985
  17. Busse WW. Biological treatments for severe asthma: A major advance in asthma care. Allergol Int. 2019;68(2):158–166. doi: 10.1016/j.alit.2019.01.004
  18. Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347–1358. doi: 10.1016/j.jaci.2016.03.010
  19. Akdis M, Aab A, Altunbulakli C, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138(4):984–1010. doi: 10.1016/j.jaci.2016.06.033
  20. Sugita K, Steer CA, Martinez-Gonzalez I, et al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):300–310.e11. doi: 10.1016/j.jaci.2017.02.038
  21. Sugita K, Altunbulakli C, Morita H, et al. Human type 2 innate lymphoid cells disrupt skin keratinocyte tight junction barrier by IL-13. Allergy. 2019;74(12):2534–2537. doi: 10.1111/all.13935
  22. Xiong Y, Cui X, Li W, et al. BLT1 signaling in epithelial cells mediates allergic sensitization via promotion of IL-33 production. Allergy. 2019;74(3):495–506. doi: 10.1111/all.13656
  23. Papadopoulos NG, Barnes P, Canonica GW, et al. The evolving algorithm of biological selection in severe asthma. Allergy. 2020;75(7):1555–1563. doi: 10.1111/all.14256
  24. Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582–1605. doi: 10.1111/all.14318
  25. Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals Inc. Dupixent (dupilumab) injection: US prescribing information. 2019. Available from: http://www.acces sdata.fda.gov
  26. Shirley M. Dupilumab: first global approval. Drugs. 2017;77(10):1115–1121. doi: 10.1007/s40265-017-0768-3.

Supplementary files

Supplementary Files
Action
1. Fig. 1. Patient’s S facial skin., 7 years old, before treatment: intense hyperemia, pronounced dryness of the skin, multiple papular rashes, crusts, excoriation.

Download (127KB)
2. Fig. 2. Patient’s S neck skin., 7 years old, before treatment: intense hyperemia, pronounced dryness of the skin, multiple papular rashes, crusts, excoriation.

Download (132KB)
3. Fig. 3. Patient’s S skin of the back., 7 years old, before treatment: intense hyperemia, pronounced dryness of the skin, multiple papular rashes, crusts, excoriation.

Download (108KB)
4. Fig. 4. Patient’s S skin of the trunk., 7 years old, after the 3rd injection of dupilumab: the intensity of hyperemia, the severity of dry skin, peeling, the number of papular rashes, excoriation significantly decreased.

Download (146KB)

Statistics

Views

Abstract: 346

PDF (Russian): 6

PDF (English): 3

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright © Pharmarus Print Media, 2021



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies